TY - JOUR
T1 - Increased expression of β-N-acetylglucosaminidase in erythrocytes from individuals with pre-diabetes and diabetes
AU - Park, Kyoungsook
AU - Saudek, Christopher D.
AU - Hart, Gerald Warren
PY - 2010/7
Y1 - 2010/7
N2 - OBJECTIVE - O-linked β-N-acetylglucosamine (O-GlcNAc) plays an important role in the development of insulin resistance and glucose toxicity. O-GlcNAcylation is regulated by O-GlcNAc transferase (OGT), which attaches O-GlcNAc to serine and/or threonine residues of proteins and by O-GlcNAcase, which removes O-Glc-NAc. We investigated the expression of these two enzymes in erythrocytes of human subjects with diabetes or pre-diabetes. RESEARCH DESIGN AND METHODS - Volunteers with normal condition, pre-diabetes, and diabetes were recruited through a. Digestive and Kidney Diseases) study and at the Johns Hopkins Comprehensive Diabetes Center. Erythrocyte proteins were extracted and hemoglobins were depleted. Global O-GlcNAcylation of erythrocyte proteins was confirmed by Western blotting using an O-GlcNAc-specific antibody. Relative OGT and O-GlcNAcase protein amounts were determined by Western blot analysis. Relative expression of O-GlcNAcase was compared with the level of A1C. RESULTS - Erythrocyte proteins are highly O-GlcNAcylated. O-GlcNAcase expression is significantly increased in erythrocytes from both individuals with pre-diabetes and diabetes compared with normal control subjects. Unlike O-GlcNAcase, protein levels of OGT did not show significant changes. CONCLUSIONS - O-GlcNAcase expression is increased in erythrocytes from both individuals with pre-diabetes and individuals with less well-controlled diabetes. These findings, together with the previous study that demonstrated the increased site-specific O-GlcNAcylation of certain erythrocyte proteins, suggest that the upregulation of O-GlcNAcase might be an adaptive response to hyperglycemia-induced increases in O-GlcNAcylation, which are likely deleterious to erythrocyte functions. In any case, the early and substantial upregulation of O-GlcNAcase in individuals with pre-diabetes may eventually have diagnostic utility.
AB - OBJECTIVE - O-linked β-N-acetylglucosamine (O-GlcNAc) plays an important role in the development of insulin resistance and glucose toxicity. O-GlcNAcylation is regulated by O-GlcNAc transferase (OGT), which attaches O-GlcNAc to serine and/or threonine residues of proteins and by O-GlcNAcase, which removes O-Glc-NAc. We investigated the expression of these two enzymes in erythrocytes of human subjects with diabetes or pre-diabetes. RESEARCH DESIGN AND METHODS - Volunteers with normal condition, pre-diabetes, and diabetes were recruited through a. Digestive and Kidney Diseases) study and at the Johns Hopkins Comprehensive Diabetes Center. Erythrocyte proteins were extracted and hemoglobins were depleted. Global O-GlcNAcylation of erythrocyte proteins was confirmed by Western blotting using an O-GlcNAc-specific antibody. Relative OGT and O-GlcNAcase protein amounts were determined by Western blot analysis. Relative expression of O-GlcNAcase was compared with the level of A1C. RESULTS - Erythrocyte proteins are highly O-GlcNAcylated. O-GlcNAcase expression is significantly increased in erythrocytes from both individuals with pre-diabetes and diabetes compared with normal control subjects. Unlike O-GlcNAcase, protein levels of OGT did not show significant changes. CONCLUSIONS - O-GlcNAcase expression is increased in erythrocytes from both individuals with pre-diabetes and individuals with less well-controlled diabetes. These findings, together with the previous study that demonstrated the increased site-specific O-GlcNAcylation of certain erythrocyte proteins, suggest that the upregulation of O-GlcNAcase might be an adaptive response to hyperglycemia-induced increases in O-GlcNAcylation, which are likely deleterious to erythrocyte functions. In any case, the early and substantial upregulation of O-GlcNAcase in individuals with pre-diabetes may eventually have diagnostic utility.
UR - http://www.scopus.com/inward/record.url?scp=77954308587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954308587&partnerID=8YFLogxK
U2 - 10.2337/db09-1086
DO - 10.2337/db09-1086
M3 - Article
C2 - 20413512
AN - SCOPUS:77954308587
SN - 0012-1797
VL - 59
SP - 1845
EP - 1850
JO - Diabetes
JF - Diabetes
IS - 7
ER -